TALEN-mediated Nanog disruption results in less invasiveness, more chemosensitivity and reversal of EMT in Hela cells

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8393-8401

  Ding, Yan ^a,b   Yu, Ai Qing ^a   Li, Cheng Lin ^a   Fang, Juan ^a   Zeng, Yi ^b   Li, Dong Sheng ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Cervical cancer cell; Epithelial mesenchymal transition; Hela cell; Nanog; TALEN

Indexed keywords

CISPLATIN; NERVE CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXD3; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; DEOXYRIBONUCLEASE; HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN;

ALLELE; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL INVASION; CELL RENEWAL; CERVICAL CANCER CELL LINE; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; E CADHERIN GENE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOXD3 GENE; GENE; GENE DISRUPTION; GENE MUTATION; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; N CADHERIN GENE; NANOG GENE; NONHUMAN; OCT4 GENE; PROTEIN EXPRESSION; SOX2 GENE; TALEN GENE; UPREGULATION; UTERINE CERVIX CANCER; VIMENTIN GENE; XENOGRAFT; ANIMAL; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; RNA EDITING; TIME; TUMOR INVASION; TUMOR VOLUME; UTERINE CERVICAL NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL SURVIVAL; CISPLATIN; DEOXYRIBONUCLEASES; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HOMEODOMAIN PROTEINS; HUMANS; MICE, NUDE; MUTATION; NEOPLASM INVASIVENESS; PACLITAXEL; RNA EDITING; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907991956     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2298     Document Type: Article

References (23)

1. Jemal A1, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Liu X, Wang D, Liu H, Feng Y, Zhu T, Zhang L, Zhu B, Zhang Y. Knockdown of astrocyte elevated gene-1 (AEG-1) in cervical cancer cells decreases their invasiveness, epithelial to mesenchymal transition, and chemoresistance. Cell Cycle. 2014; 13:11, 1-6.
3. Kim CJ, Jeong JK, Park M, Park TS, Park TC, Namkoong SE, Park JS. HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions. Gynecol Oncol. 2003; 89:210-217.
4. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003; 113: 643-655.
5. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003; 113: 631-642.
6. Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt SN, Borges I, Ruizi Altaba A. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J. 2010; 29: 2659-2674.
7. Freberg CT, Dahl JA, Timoskainen S, Collas P. Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. Mol Biol Cell. 2007; 18: 1543-1553.
8. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 2007; 67: 4807-4815.
9. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008; 40: 499-507.
10. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, Calhoun-Davis T, Zaehres H, Daley GQ, Tang DG. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells. 2009; 27: 993-1005.
11. Jeter CR, Liu B, Liu X, Chen X, Liu C, Calhoun-Davis T, Repass J, Zaehres H, Shen JJ, Tang DG. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene. 2011; 30: 3833-3845.
12. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, Dulay GP, Hua KL, Ankoudinova I, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. 2011; 29: 143-148.
13. Cade L, Reyon D, Hwang WY, Tsai SQ, Patel S, Khayter C, Joung JK, Sander JD, Peterson RT, Yeh JR. Highly efficient generation of heritable zebrafish gene mutations using homo-and heterodimeric TALENs. Nucleic Acids Res. 2012; 40: 8001-8010.
14. Landry JJ, Pyl PT, Rausch T, Zichner T, Tekkedil MM, Stütz AM, Jauch A, Aiyar RS, Pau G, Delhomme N, Gagneur J, Korbel JO, Huber W, Steinmetz LM. The Genomic and Transcriptomic Landscape of a HeLa Cell Line. G3 (Bethesda). 2013; 3: 1213-1224.
15. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, Calhoun-Davis T, Zaehres H, Daley GQ, Tang DG. The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line. Nature. 2013; 500: 207-211.
16. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
17. Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol. 2000; 148:399-404.
18. Hao L, Ha JR, Kuzel P, Garcia E, Persad S. Cadherin switch from E-to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail. Br J Dermatol. 2012; 166:1184-1197.
19. Hendrix MJ, Seftor EA, Chu YW, Trevor KT, Seftor RE. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metastasis Rev. 1996; 15:507-525.
20. Sagawa Y, Fujitoh A, Nishi H, Ito H, Yudate T, Isaka K. Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure. Tumour Biol. 2011; 32:399-408.
21. Ding ZY, Liu GH, Olsson B, Sun XF. Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells. Tumour Biol. 2013; 34:683-693.
22. Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006; 13: 1859-1876.
23. Goda K, Bacsó Z and Szabó G. Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets. 2009; 9: 281-297.